Strategic partnerships Opportunity to engage ONO PHARMA USA in co-development or licensing discussions leveraging their oncology, immunology, neurology, and specialty medicine focus, and their track record with high-impact therapies.

Immunotherapy leadership Position as a supplier or collaborator for immunotherapy-related tools, services, or biomarkers given ONO's history with first-in-class therapies and ongoing immuno-oncology programs.

Fibro-inflammatory collaboration Target Mediar Therapeutics partnership as a gateway to fibro-inflammatory disease programs, offering expertise, analytics, or platform services to accelerate discovery and antibody development.

Drug discovery tech Offer AI-powered discovery platforms, biomarker identification, or data integration services (e.g., Biomni Lab collaboration) to accelerate their preclinical pipelines and reduce cycle times.

Global market access Leverage ONO’s global footprint and US subsidiary presence to present integrated commercialization, regulatory, and market access solutions for cross-border launches and regional expansion.